Resource Logo
CDC HIV/AIDS/Viral Hepatitis/STD/TB Prevention News Update

GLOBAL: Alarming Levels of Drug-Resistant TB Found Worldwide


Reuters (08.30.12)

A large international study published Thursday shows rates of both multidrug-resistant TB (MDR TB) and extensively drug-resistant TB (XDR TB) in Africa, Asia, Europe, and Latin America are much higher than previously thought. MDR TB is resistant to at least two first-line treatments - isoniazid and rifampicin - and XDR TB is resistant to these two as well as fluoroquinolone and a second-line injectable antibiotic. The rise of drug-resistant TB is partly due to patients failing to complete the lengthy six-month regimen of powerful antibiotics used to treat regular TB. Treatment for drug-resistant TB can cost 200 times more than regular TB and take up to two years to complete, said Tom Evans, chief scientific officer at Aeras, a nonprofit working to develop new TB vaccines. Medical options for XDR TB patients, he said, are “limited, expensive, and toxic.” CDC’s Tracy Dalton, who led the study, said the spread of drug-resistant TB is “particularly worrisome” in areas with limited health care resources and poor access to effective drugs. So far, she said, XDR TB has been reported in 77 countries worldwide. “As more individuals are diagnosed with, and treated for, drug-resistant TB, more resistance to second-line drugs is expected to emerge,” she noted. The study found resistance to at least one second-line TB drug in nearly 44 percent of patients overall, ranging from 33 percent in Thailand to 62 percent in Latvia. In about one-fifth of cases, resistance was seen to at least one second-line injectable drug, ranging from 2 percent in the Philippines to 47 percent in Latvia. XDR TB was detected in 6.7 percent of patients overall. XDR TB rates in South Korea (15.2 percent) and Russia (11.3 percent) were more than double the World Health Organization’s global estimate of 5.4 percent. [PNU editor’s note: The study, “Prevalence of and Risk Factors for Resistance to Second-Line Drugs in People with Multidrug-Resistant Tuberculosis in Eight Countries: A Prospective Cohort Study,” was published in The Lancet (2012;doi:10.1016/S0140-6736(12)60734-X).]


Copyright © 2012 -CDC Prevention News Update, Publisher. All rights reserved to Information, Inc., Bethesda, MD. The CDC National Center for HIV, STD and TB Prevention provides the following information as a public service only. Providing synopses of key scientific articles and lay media reports on HIV/AIDS, other sexually transmitted diseases and tuberculosis does not constitute CDC endorsement. This daily update also includes information from CDC and other government agencies, such as background on Morbidity and Mortality Weekly Report (MMWR) articles, fact sheets, press releases and announcements. Reproduction of this text is encouraged; however, copies may not be sold, and the CDC HIV/STD/TB Prevention News Update should be cited as the source of the information. Contact the sources of the articles abstracted below for full texts of the articles.

Information in this article was accurate in August 31, 2012. The state of the art may have changed since the publication date. This material is designed to support, not replace, the relationship that exists between you and your doctor. Always discuss treatment options with a doctor who specializes in treating HIV.